You just read:

Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

News provided by

Wize Pharma, Inc.

Mar 28, 2018, 02:25 ET